Decade in review: a new era for RET-rearranged lung cancers

por Choudhury, Noura J., Drilon, Alexander
Publicado 2020

Targeting RET-rearranged lung cancers with multikinase inhibitors

por Sabari, Joshua K., Siau, Evan D., Drilon, Alexander
Publicado 2017

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

por Liu, Dazhi, Offin, Michael, Harnicar, Stephen, Li, Bob T, Drilon, Alexander
Publicado 2018

RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity

por Desilets, Antoine, Repetto, Matteo, Yang, Soo-Ryum, Sherman, Eric J., Drilon, Alexander
Publicado 2023

CT features of HER2-mutant lung adenocarcinomas

por Sawan, Peter, Plodkowski, Andrew J., Li, Angela E., Li, Bob T., Drilon, Alexander, Capanu, Marinela, Ginsberg, Michelle S.
Publicado 2018

Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target

por Cook, Peter J., Thomas, Rozario, Kannan, Ram, de Leon, Esther Sanchez, Drilon, Alexander, Rosenblum, Marc K., Scaltriti, Maurizio, Benezra, Robert, Ventura, Andrea
Publicado 2017

Author Correction: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target

por Cook, Peter J., Thomas, Rozario, Kannan, Ram, de Leon, Esther Sanchez, Drilon, Alexander, Rosenblum, Marc K., Scaltriti, Maurizio, Benezra, Robert, Ventura, Andrea
Publicado 2018

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers

por Sabari, Joshua K, Santini, Fernando C, Schram, Alison M, Bergagnini, Isabella, Chen, Ruqin, Mrad, Chebli, Lai, W Victoria, Arbour, Kathryn C, Drilon, Alexander
Publicado 2017

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases

por Guo, Robin, Schreyer, Mark, Chang, Jason C., Rothenberg, S. Michael, Henry, Dahlia, Cotzia, Paolo, Kris, Mark G., Rekhtman, Natasha, Young, Robert J., Hyman, David M., Drilon, Alexander
Publicado 2019

Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors

por Rosen, Ezra Y., Schram, Alison M., Young, Robert J., Schreyer, Mark W., Hechtman, Jaclyn F., Shu, Catherine A., Ku, Nora C., Hyman, David M., Drilon, Alexander
Publicado 2019

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

por Goldman, Jonathan W., Sholl, Lynette M., Dacic, Sanja, Fishbein, Michael C., Murciano-Goroff, Yonina R., Rajaram, Ravi, Szymczak, Sylwia, Szpurka, Anna M., Chao, Bo H., Drilon, Alexander
Publicado 2023

Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment

por Liu, Dazhi, Weintraub, Michael A., Garcia, Christine, Goncalves, Marcus D., Sisk, Ann Elizabeth, Casas, Alissa, Harding, James J., Harnicar, Stephen, Drilon, Alexander, Jhaveri, Komal, Flory, James H.
Publicado 2022

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors

por Calvo, Emiliano, Sessa, Cristiana, Harada, Guilherme, de Miguel, Maria, Kahatt, Carmen, Luepke-Estefan, Xarles Erik, Siguero, Mariano, Fernandez-Teruel, Carlos, Cullell-Young, Martin, Stathis, Anastasios, Drilon, Alexander
Publicado 2022

LPTO-04. GENERATION AND CHARACTERIZATION OF PATIENT-DERIVED PRECLINICAL MODELS FROM TUMOR CELLS ISOLATED FROM CEREBROSPINAL FLUID

por Offin, Michael, Vojnic, Morana, Liu, Zebing, Lui, Allan, Siau, Evan, Gladstone, Eric, Mattar, Marissa, Khodos, Inna, Drilon, Alexander, Boire, Adrienne, Rudin, Charles, De Stanchina, Elisa, Ladanyi, Marc, Somwar, Romel
Publicado 2019

Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations

por Murray, Brion W., Rogers, Evan, Zhai, Dayong, Deng, Wei, Chen, Xi, Sprengeler, Paul A., Zhang, Xin, Graber, Armin, Reich, Siegfried H., Stopatschinskaja, Shanna, Solomon, Benjamin, Besse, Benjamin, Drilon, Alexander
Publicado 2021

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

por Somwar, Romel, Hofmann, Nicolle E., Smith, Bryan, Odintsov, Igor, Vojnic, Morana, Linkov, Irina, Tam, Ashley, Khodos, Inna, Mattar, Marissa S., de Stanchina, Elisa, Flynn, Daniel, Ladanyi, Marc, Drilon, Alexander, Shinde, Ujwal, Davare, Monika A.
Publicado 2020

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

por Drilon, Alexander, Tan, Daniel S. W., Lassen, Ulrik N., Leyvraz, Serge, Liu, Yongmei, Patel, Jyoti D., Rosen, Lee, Solomon, Benjamin, Norenberg, Ricarda, Dima, Laura, Brega, Nicoletta, Shen, Lin, Moreno, Victor, Kummar, Shivaani, Lin, Jessica J.
Publicado 2022

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer

por Suzawa, Ken, Offin, Michael, Schoenfeld, Adam J., Plodkowski, Andrew J., Odintsov, Igor, Lu, Daniel, Lockwood, William W., Arcila, Maria E., Rudin, Charles M., Drilon, Alexander, Yu, Helena A., Riely, Gregory J., Somwar, Romel, Ladanyi, Marc
Publicado 2019

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

por Dziadziuszko, Rafal, Hung, Tiffany, Wang, Kun, Choeurng, Voleak, Drilon, Alexander, Doebele, Robert C., Barlesi, Fabrice, Wu, Charlie, Dennis, Lucas, Skoletsky, Joel, Woodhouse, Ryan, Li, Meijuan, Chang, Ching‐Wei, Simmons, Brian, Riehl, Todd, Wilson, Timothy R.
Publicado 2022

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

por Drilon, Alexander, Rekhtman, Natasha, Arcila, Maria, Wang, Lu, Ni, Andy, Albano, Melanie, Van Voorthuysen, Martine, Somwar, Romel, Smith, Roger S., Montecalvo, Joseph, Plodkowski, Andrew, Ginsberg, Michelle S., Riely, Gregory J., Rudin, Charles M., Ladanyi, Marc, Kris, Mark G.
Publicado 2016